

What is claimed is:

- 5 *Sub A*
1. A method for treating a human patient having a resectable malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient, then surgically resecting said malignant tumor.

Sub. 2
432

2. The method of claim 1 wherein said immunostimulatory dosage is about 3,000,000 U/m² per day or less.

10 3. The method of claim 1 wherein said immunostimulatory dosage is about 1,000,000 U/m² per day or less.

4. The method of claim 1 wherein said immunostimulatory dosage is about 500,000 U/m² per day or less.

5. The method of claim 1 wherein said immunostimulatory dosage is about 250,000 U/m² per day or less.

15 6. ~~The method of claim 1 wherein said immunostimulatory dosage is about 100,000 U/m² per day or less.~~

20 7. The method of claim 1 further comprising administering said immunostimulatory dosage for about five days prior to resecting said malignant tumor.

Ins Co

8. The method of claim 7 wherein said dosage is administered once per day.

25 9. The method of claim 7 wherein said immunostimulatory dosage increases NK lymphocyte cytotoxicity at least about 50% above the NK lymphocyte cytotoxicity

- 5 11.
- INS
CB

- 10

- [illegible]

- 15

- ~~15. The method of claim 7 wherein said immunostimulatory dosage increases T-lymphocyte activation.~~

- 20

18. The method of claim 17 wherein said solid tumor is selected from the group consisting of breast cancer, lung cancer, pancreatic cancer, brain cancer,

- 24 -

Sub
A²

prostate cancer, ovarian cancer, uterine cancer, renal cancer, and melanoma.

- Sub
A2
cut
19. The method of claim 18 wherein said solid tumor is an early-stage solid tumor.
- 5 20. The method of claim 17 wherein said solid tumor is an early-stage solid tumor.

21. The method of claim 1 wherein said malignant tumor is a melanoma.

INS
CS

10 22. The method of claim 1 wherein said malignant tumor is a renal carcinoma.

23. A method for preventing post-operative infection comprising administering an immunostimulatory dosage of an α -interferon composition to a human before surgery.

15 24. An article of manufacture comprising packaging material and an α -interferon composition contained within said packaging material, wherein said packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α -interferon composition followed by surgical resection of a malignant tumor can be effective for treating a human patient having said malignant tumor.

20
A3

25 25. An article of manufacture comprising packaging material and an α -interferon composition contained within said packaging material, wherein said

packaging material comprises a label or package insert indicating that administration of an immunostimulatory dosage of said α -interferon composition in conjunction with treating said patient using effective non-surgical medical methodologies for diminishing said malignant tumor can be effective for treating a human patient having said malignant tumor.

5

26.

A method for treating a human patient having a non-resectable malignant tumor, comprising administering an immunostimulatory dosage of an α -interferon composition to said patient and treating said patient with effective non-surgical medical methodologies to diminish said tumor.

10

18244.M11